Corporate | 26 April 2016 10:00

STADA Arzneimittel AG: Successful refinancing through the securing of additional promissory note loans of a total of Euro 350 million

DGAP-News: STADA Arzneimittel AG / Key word(s): Miscellaneous

2016-04-26 / 10:00
The issuer is solely responsible for the content of this announcement.

Press release

STADA: Successful refinancing through the securing of additional promissory note loans of a total of Euro 350 million

Bad Vilbel, April 26, 2016 – STADA Arzneimittel AG has secured additional promissory note loans of a total of Euro 350 million. With the new promissory note loans, STADA has refinanced promissory note loans in the amount of Euro 188.0 million, which will expire in December 2016.

The promissory note loans, which are divided into four tranches and have terms of between five and seven years, have both fixed and variable interest rates. The securing of the refinancing sum will result in significant annual interest savings in future.

“As a result of the high demand from numerous promissory note investors, we were able to place a much higher volume than originally planned. The successful transaction highlights STADA’s access to the debt market and allows us to further expand our maturity profile at attractive conditions. Overall, we are therefore well-equipped for future growth”, says Helmut Kraft, Chief Financial Officer of STADA Arzneimittel AG, of the successful refinancing.

The transaction was supported by Landesbank Hessen-Thüringen and Landesbank Baden-Württemberg.

Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail: ir@stada.de

Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad Vilbel – Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail: press@stada.de

Or visit us in the Internet at www.stada.com .

2016-04-26 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

Language:	English
Company:	STADA Arzneimittel AG
	Stadastraße 2-18
	61118 Bad Vilbel
	Germany
Phone:	+49 (0)6101 603- 113
Fax:	+49 (0)6101 603- 506
E-mail:	communications@stada.de
Internet:	www.stada.de
ISIN:	DE0007251803, DE0007251845,
WKN:	725180, 725184,
Indices:	MDAX
Listed:	Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Hanover, Munich, Stuttgart; Terminbörse EUREX

End of News DGAP News Service